Drug Sponsors

AstraZeneca collaborates to use CRISPR technology

Friday, January 30, 2015 12:27 PM

AstraZeneca has announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The four research collaborations are with the Wellcome Trust Sanger Institute, Cambridge, U.K.; the Innovative Genomics Initiative, California; Thermo Fisher Scientific, Waltham, Mass.; and the Broad Institute/Whitehead Institute, Cambridge, Mass. The technology will allow AZ to identify and validate new drug targets in preclinical models that closely resemble human disease.

More... »


Regulatory update on GSK-Novartis three-part transaction

Thursday, January 29, 2015 12:25 PM

GlaxoSmithKline has received clearance from the European Commission (E.C.) of its proposed three-part transaction with Novartis, which includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.

More... »


3SBio acquires Sirton Pharmaceuticals

Monday, January 26, 2015 02:25 PM

3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.

More... »

Actavis to acquire Auden Mckenzie for $461.8 million

Monday, January 26, 2015 02:24 PM

Actavis, a global specialty pharmaceutical company, will acquire Auden Mckenzie, a company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the U.K., for approximately $461.8 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products.

More... »

BIO responds to President Obama's State of the Union speech

Friday, January 23, 2015 11:53 AM

The Biotechnology Industry Organization (BIO), a trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations, has issued a statement in response to President Obama's State of the Union speech.

More... »

Syncona, UCLB form Autolus cancer immunotherapy company

Friday, January 23, 2015 11:47 AM

Syncona, a London-based subsidiary of the Wellcome Trust, and UCL Business, the wholly-owned technology transfer company of University College London (UCL), have announced the creation of Autolus, a London-based biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for hematological and solid tumors. Autolus is founded upon the work of Dr. Martin Pule, an academic clinical hematologist and thought-leader in T-cell engineering. Syncona has committed $33.5 million to Autolus in a Series A financing. Dr. Christian Itin, former CEO of Micromet, has joined the company as chairman.

More... »

Academy of Medical Royal Colleges not supporting Medical Innovation Bill

Friday, January 23, 2015 11:43 AM

The Academy of Medical Royal Colleges has released a statement on the proposed Medical Innovation Bill.

More... »

AbbVie Innovation Center opens at the University of Illinois Research Park

Thursday, January 22, 2015 12:18 PM

AbbVie, a global research-based biopharmaceutical company based in North Chicago, Ill., has opened the AbbVie Innovation Center on campus at the University of Illinois Research Park in Urbana-Champaign.

More... »

SV Bio renames itself Lifecode, launches oncology assay

Thursday, January 22, 2015 12:17 PM

Silicon Valley Biosystems (SV Bio) has changed its name to Lifecode. The new name is consistent with the company's mission to improve the lives of patients by providing concise, accurate and actionable molecular information. Lifecode also has released its flagship next generation sequencing (NGS)-based oncology assay, the Pan Cancer Somatic Panel (PCSP), to a select group of physicians nationwide in advance of a broad launch later this spring.

More... »

Roche acquires Trophos to expand neuromuscular disease portfolio

Wednesday, January 21, 2015 01:00 PM

Roche has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. The company has developed a proprietary cholesterol-oxime based chemistry platform. Trophos's mitochondrial targeted compounds enhance the function and survival of stressed cells by preventing mitochondrial permeability transition, a key determinant of cell death or survival.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs